Our Pricing

Best Price For Wegovy UK: All Doses Available

Published on: June 03, 2026

Searching for the best price for Wegovy UK? At Cured Pharmacy, Wegovy (semaglutide) weight loss injections start from £79.00, with all doses available and transparent upfront pricing before your free online consultation. Our UK-registered clinical team provides prescription assessment in under 3 minutes, with discreet delivery direct to your door.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural hormone glucagon-like peptide-1, which regulates appetite and food intake by acting on brain receptors that control hunger signals.

In the landmark STEP 1 trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing appetite, and improving glycaemic control, making it significantly more effective than lifestyle modifications alone [2].

Wegovy Dosing Schedule and Best Price for Wegovy UK

Wegovy follows a gradual dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic response. Treatment begins with 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg, before reaching the maintenance dose of 2.4mg weekly [3].

At Cured Pharmacy, we stock all Wegovy doses with pricing from £79.00, ensuring continuity throughout your treatment journey. Our transparent pricing model shows costs before consultation, and all prescriptions are issued by UK-registered prescribers following clinical assessment. This approach eliminates hidden fees and provides certainty around your monthly treatment costs.

Dose Titration and Clinical Monitoring

The dose escalation schedule is clinically important — rushing to higher doses increases the risk of nausea, vomiting, and treatment discontinuation. Our prescribers assess your tolerance at each stage and may adjust the titration speed based on your individual response. Regular monitoring ensures you receive the optimal therapeutic dose whilst managing side effects effectively.

Wegovy vs Other Weight Loss Treatments

Several prescription weight loss medications are now available through UK pharmacies, each with distinct mechanisms and efficacy profiles. Wegovy's once-weekly injection offers convenience compared to daily alternatives, and clinical trial data demonstrates superior weight loss outcomes versus older treatments.

Semaglutide-based Wegovy differs from tirzepatide treatments through its single GLP-1 receptor pathway, whilst oral medications like orlistat work by blocking fat absorption rather than appetite regulation. Your UK prescriber will recommend the most appropriate treatment based on your medical history, BMI, comorbidities, and lifestyle factors.

Choosing Between Injectable Options

Both semaglutide and tirzepatide injections require prescription and clinical monitoring. Factors influencing treatment choice include previous medication tolerance, injection frequency preference, and specific health conditions. Our clinical team provides personalised recommendations during your free consultation, ensuring the selected treatment aligns with your weight loss goals and medical profile.

Clinical Evidence: STEP Trial Programme Results

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme represents the most comprehensive evidence base for Wegovy's efficacy. Across five major trials involving over 4,500 participants, semaglutide consistently demonstrated significant weight reduction compared to placebo and active comparators [1][2].

STEP 2 specifically examined patients with type 2 diabetes, showing an average 9.6% weight loss over 68 weeks — addressing both glycaemic control and obesity simultaneously [4]. These results led to NICE guidance supporting semaglutide use in specialist weight management services, and subsequent MHRA licensing for broader clinical use in the UK.

Importantly, trial data shows that weight loss plateaus around 60-68 weeks, with most reduction occurring in the first year of treatment [1]. Participants who discontinued treatment experienced gradual weight regain, highlighting the importance of long-term adherence and lifestyle modifications alongside pharmacotherapy.

Who Can Use Wegovy in the UK

Wegovy is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [3]. It's prescribed as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone treatment.

Certain medical conditions preclude Wegovy use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and diabetic retinopathy complications [3]. Pregnancy and breastfeeding are also contraindications, and women of childbearing potential should use effective contraception during treatment.

Our UK prescribers conduct thorough medical assessments during your online consultation, reviewing your full medical history, current medications, and treatment goals. This ensures Wegovy is both safe and clinically appropriate for your individual circumstances before any prescription is issued.

Pre-Treatment Considerations

Before starting Wegovy, discuss any history of pancreatitis, gallbladder disease, kidney problems, or mental health conditions with your prescriber. These factors don't necessarily prevent treatment but require additional monitoring. Your prescriber will also assess potential drug interactions, particularly with other diabetes medications or treatments affecting gastric motility.

Managing Side Effects and Treatment Expectations

The most common side effects of Wegovy are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal pain [3]. These typically occur during dose escalation and diminish as your body adapts to the medication. In clinical trials, most gastrointestinal events were mild to moderate and transient.

To minimise side effects, eat smaller meals, avoid high-fat foods, stay well-hydrated, and take your injection on the same day each week. If nausea persists, your prescriber may slow the dose escalation or recommend anti-nausea strategies. Severe or persistent symptoms warrant clinical review to rule out complications like pancreatitis or gallbladder inflammation.

Realistic expectations are crucial for treatment success. Wegovy is not a quick fix — average weight loss of 15% over 68 weeks means approximately 1-2 pounds per week for most patients [1]. Results vary based on adherence, diet quality, physical activity levels, and individual metabolic factors. Our clinical team provides ongoing support to optimise outcomes and address any concerns throughout your treatment journey.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Novo Nordisk Limited. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.